Swarali Tadwalkar, Author at tHEORetically Speaking

0

Drug Pricing Value Assessment Methods in the United States: The National Pharmaceutical Council Viewpoint

Posted on August 17, 2015 by Swarali Tadwalkar

Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Drug prices are the fastest-growing part of healthcare costs, and everyone – from patients, to physicians, policy-makers, and pharmaceutical companies – are grappling with price-setting and drug value assessment.… Continue Reading →

0

Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States

Posted on August 8, 2015 by Swarali Tadwalkar

Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Hardly a day goes by without a new article being published in the mainstream press or a medical journal discussing drug pricing. The cost of drugs is a hot… Continue Reading →

0

Good, Bad, or Indifferent on Drug Pricing: A Value Benchmark Approach for Newly Launched Drugs in the United States.

Posted on July 30, 2015 by Swarali Tadwalkar

Hardly a day goes by without a new article being published in the mainstream press or a medical journal discussing drug pricing. The cost of drugs is a hot potato topic at medical meetings, pharma conference rooms, government hearings, and… Continue Reading →